Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement
- PMID: 35536260
- DOI: 10.1001/jama.2022.5692
Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement
Abstract
Importance: Chronic obstructive pulmonary disease (COPD) is an irreversible reduction of airflow in the lungs. Progression to severe disease can prevent participation in normal activities because of deterioration of lung function. In 2020 it was estimated that approximately 6% of US adults had been diagnosed with COPD. Chronic lower respiratory disease, composed mainly of COPD, is the sixth leading cause of death in the US.
Objective: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a reaffirmation evidence update that focused on targeted key questions for benefits and harms of screening for COPD in asymptomatic adults and treatment in screen-detected or screen-relevant adults.
Population: Asymptomatic adults who do not recognize or report respiratory symptoms.
Evidence assessment: Using a reaffirmation process, the USPSTF concludes with moderate certainty that screening for COPD in asymptomatic adults has no net benefit.
Recommendation: The USPSTF recommends against screening for COPD in asymptomatic adults. (D recommendation).
Comment in
-
Screening for Chronic Obstructive Pulmonary Disease: Challenges and Opportunities.JAMA. 2022 May 10;327(18):1768-1770. doi: 10.1001/jama.2022.3823. JAMA. 2022. PMID: 35536275 No abstract available.
Summary for patients in
-
Screening for Chronic Obstructive Pulmonary Disease.JAMA. 2022 May 10;327(18):1831. doi: 10.1001/jama.2022.6110. JAMA. 2022. PMID: 35536265 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
